Please note that we have stopped the regular imports of Gene Expression Omnibus (GEO) data into ArrayExpress. This may not be the latest version of this experiment.
E-GEOD-33552 - Expression data from MDA-MB-231 cell line treated with Zoledronate, or Fluvastatin, or mock-treated control cells
Released on 1 January 2012, last updated on 17 August 2015
Statins and bisphosponates (BPs) are two distinct classes of isoprenoid pathway inhibitors targeting HMG-CoA reductase (upstream enzyme) and Farnesyl-pyrophospate synthase (downstream enzyme) respectively. Here we conducted a comparative study of two representatives of these classes, fluvastatin (Fluva) and Zoledronate (Zol), to assess the differences in their in vivo metastatic potentials and pharmacogenomic profiles. Both drugs, being administered after emergence of detectable metastases, appeared to be potent metastasis inhibitors in MDA-MB-231 breast cancer metastasis model. We observed a reduced number of metastatic sites under Fluva, but not Zol treatment. Combinatorial in vivo treatment by Fluva and Zol showed no synergy for these drugs, as reported earlier on the basis of in vitro studies (Budman DR, Oncology 2006), staying in line with similarity of their transcriptomic profiles. Comparison of Zol and Fluva transcriptomic profiles revealed similar patterns of affected genes (describe involved genes functions) through different kinetics (when treated with IC50 determined for 72h treatment, the majority of changes were observed after 24h incubation with Fluva , and only after 48h incubation with Zol at 72h-IC50 or after 24h treatment with its 3 times higher dose). We demonstrated here that targeting different enzymes of the same pathway neither necessarily leads to distinct changes in gene profiles, nor to synergy for in vivo anti-metastatic potential. Subconfluent MDA-MB-321 cells were treated with 2 µM Fluvastatine or 30 µM Zoledronate (concentrations corresponding to IC50 at 72h treatment) for 12h and 24h , or treated with Zoledronate for longer time (48h at 30 µM) or with higher concentration (24h at 100 µM of Zoledronate ). Mock-treated (control) cells were obtained in parallel for each time point. Four independent replicates were used for each condition. Total of 40 samples were analyzed (10 conditions with 4 replicates for each). To determine differentially expressed genes, differences between treated cells versus corresponding mock-treated control were calculated using R-Bioconductor statistical environment. Pairing was made to remove source of variation due to the day of measurement in the comparison between the two conditions.
transcription profiling by array
Jean-Philippe Jais, Melanie Di Benedetto, Nadejda Vintonenko
Transcriptome analysis and in vivo activity of fluvastatin versus zoledronic acid in a murine breast cancer metastasis model. Vintonenko N, Jais JP, Kassis N, Abdelkarim M, Perret GY, Lecouvey M, Crepin M, Di Benedetto M.